Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine is one of the...

• CSI 300;
• Forbes Global 2000 (#1415).

Jiangsu Hengrui Medicine is a company listed under the stock ticker 600276 (CN).

View the org chart displaying its 8 main executives

Most searched biographies at Jiangsu Hengrui Medicine

• Shuang Xue, Independent Director
• Congzhao Guo, Director
• Piaoyang Sun, Director

Create your alert
to follow the executive moves at Jiangsu Hengrui Medicine.

Jiangsu Hengrui Medicine has 1,865 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Jiangsu Hengrui Medicine

• 恒瑞医药
• 恒瑞医药

Social media about Jiangsu Hengrui Medicine

• Jiangsu Hengrui Medicine on Wikipedia, Google News & Yahoo Finance
• Jiangsu Hengrui Medicine on LinkedIn, Twitter & YouTube

Contact by email its executives including Jiang Ningjun

Call Jiangsu Hengrui Medicine at +86 400...

View the org chart

Register to receive your alert

Report an error